# Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

> **NCT04988074** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 32 (estimated)

## Conditions studied

- HPV-Related Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT04988074
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988074, "Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04988074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*